Serono Genetics Institute SA, a subsidiary of Merck KGaA, is a French company located in Paris. The firm operates a biotechnology company specializing in synthetic DNA and genetic analysis. It was founded in 1989 by Pascal Brandys. Serono Genetics Institute SA was acquired by Serono SA on September 23, 2002 for $65.82 million.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

The 301 Hospital (Chinese: 三〇一医院) or People's Liberation Army General Hospital (Chinese: 中国人民解放军总医院), which constitutes simultaneously the PLA Postgraduate Medical School (Chinese: 中国人民解放军医学院), located in Beijing, China, is a military hospital directly subsidiary to Logistic Support Department of the Central Military Commission and the largest general hospital under the auspices of the People's Liberation Army. Its mission includes assuring the health of PLA and China's leaders.

Beijing Bozhao Jiaye Technology Co., Ltd., established on 2017-08-25, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;Sell ​​self-developed products;Sales of medical devicesIkind,medical instrumentsIIkind,,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),Equipment,Groceries,knitted goods,stationery,clothing,shoes and hats,bags,Security Technology Protection Products,hygiene products,crafts,electronic product,communication equipment,computer,Software and Auxiliary Equipment;Computer System Services;Basic software service;Application software service;software development;software consulting;product design;model design;Packaging and decoration design;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Agricultural Science Research and Experimental Development;Medical Research and Experimental Development;data processing(Bank Card Center in Data Processing,PUEvalue in1.4Except for the above cloud computing data centers).(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.).

Shenzhen Aikang Reagent Co., Ltd., established on 2013-08-09, Business scope includes general business items:Computer Programming;computer software design;Economic Information Consulting(No restricted items);General Machinery,Professional setting,transportation equipment,Sales of electrical machinery;communication equipment,electronic product,Sales of instrumentation and office machinery;computer,Sales of software and auxiliary equipment;Sales of Class I medical supplies and equipment;Agricultural Technology,Biotechnology,new material technology,Energy saving technology development;Technical development of biological products;Technology development of biotechnology products;Domestic Trade;Operating import and export business.(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating),The licensing program is:Class II,Three types of medical device business;Sales of in vitro diagnostic reagents;Class II,Three categories6840Production of in vitro diagnostic reagents;Production of Class I Medical Devices.

Shanghai Kaipu Medical Laboratory Co., Ltd., established on 2016-02-02, Business scope includes for-profit medical institutions,Research and Development of Pharmaceutical Products,Medical device management,Engaged in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer,Electrical Equipment,Maintenance of instruments and meters,business inquiries,Engaged in the import and export of goods and technology,Own Equipment Rental. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Nanjing Daybreak Biotechnology Co., Ltd., established on 2016-11-16, Business scope includes licensed projects:pharmaceutical production;medical service;Production of Class III Medical Devices;Internet hospital services relying on physical hospitals;Production of Class II Medical Devices;Class III medical device business;Class III Medical Device Leasing;Inspection and testing service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Research and development of bio-based materials technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Biochemical product technology research and development;R&D and application of cell technology;Fermentation process optimization technology research and development;R&D of industrial enzyme preparations;Engineering and Technology Research and Experimental Development;Technical extension services;Technology promotion and application services;Medical Research and Experimental Development;Import and export;Technology Import and Export;Import and export agency;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Sales of new membrane materials;Manufacture of new membrane materials;Production of Class I Medical Devices;Information Technology Consulting Services;Sales of Class I Medical Devices;New material technology research and development;software development;Experimental analysis instrument sales;Sales of Class II Medical Devices;Retailing of computer software, hardware and auxiliary equipment;Information Consulting Service(Not including licensing information consulting services);Manufacturing of Drug Testing Instruments;Manufacturing of experimental analysis instruments;Class II Medical Device Leasing;Class I Medical Device Leasing(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Guangzhou Kaipu Pharmaceutical Technology Co., Ltd., established on 2015-10-09, Business scope includes medical equipment leasing;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Veterinary special equipment sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of special equipment for teaching;Teaching equipment sales;Machinery and Equipment Leasing;Computer and communication equipment rental;Storage equipment rental service;Office equipment rental service;General Equipment Repair;Special Equipment Repair;Computer and Office Equipment Repair;Sales of new energy vehicles;Auto New Car Sales;car used car sales;tram sales;Container Leasing Service;container maintenance;container sales;Sales of electric accessories for new energy vehicles;Information Consulting Service(Not including licensing information consulting services);Health Consulting Services(Does not include medical services);Socioeconomic Advisory Services;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Import and export;Technology Import and Export

Zhuhai Livzon Diagnostics, Inc. engages in the development, production, and marketing of in-vitro diagnostic (IVD) products. Its products include diagnostic kit for Immunoglobulin M (IgM) / Immunoglobulin G (IgG) antibody to coronavirus (SARS-CoV-2), autoimmunity multiple detection platform, chemiluminescence detection platform, nucleic acid molecule detection platform, and X-ray blood irradiator. The company was founded on January 26, 1989 and is headquartered in Zhuhai, China.

Shanghai Sidi Medical Laboratory Co., Ltd., established on 2015-10-26, Business scope includes for-profit medical institutions,Research on biological reagents for non-clinical diagnosis,Medical device management,Application software development,Sales,Sales of computers and auxiliary equipment,engaged in computer technology,medical technology,Technology development in the field of biotechnology,technology transfer,Technical Services,technical consulting,Biotechnology Extension Services,Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval). [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system. Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis. The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world. Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.

Fujirebio, Inc. engages in the manufacture, sale, import and export of clinical diagnostic reagents and assay instruments. It also provides diagnostic, clinical laboratory testing and related services. The company was founded on December 18, 1950 and is headquartered in Tokyo, Japan.

Wuhan Zhongzhi Biotechnologies' main product, multiple respiratory pathogen nucleic acid detection reagents, is developed based on its own core patented technology-dual amplification technology combining T7RNA isothermal amplification and multi-biotin signal amplification. The company has built a number of molecular detection technology platforms with international leading levels, including multi-biotin signal amplification technology, dual amplification technology, nucleic acid POCT rapid detection technology, etc.

Autobio Diagnostics is a company mainly engaged in development, manufacture and sales of diagnostics products.

Part of Merck KGaA, Merck Serono Biodevelopment is a company headquartered in Lyon, France, that engages in biological research and development activities. The firm was founded in 2007.

Qingdao Shuojing Biotechnology Co., Ltd., established on 2019-06-13, Business scope includes technology research and development in the field of biotechnology,Technical Services,technical consulting,technology transfer;biologically active protein,antibody protein,antigen enzyme-labeled biological protein,Research and development of antibody enzyme-labeled protein,production and sales;Research and development of reagent intermediates and consumables,production and sales;R&D of instrumentation,production and sales;Goods and technology import and export business permitted by the state.(None of the above contain hazardous chemicals and precursor chemicals)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)